Calquence (acalabrutinib) is a targeted therapy used to treat certain types of cancer. Specifically, it is a Bruton's tyrosine kinase (BTK) inhibitor approved for adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1].
What is Calquence’s mechanism of action?
Calquence works by inhibiting BTK, a protein that plays a crucial role in the growth and survival of certain white blood cells, including cancerous B cells [1]. By blocking BTK, the drug disrupts signaling pathways essential for these cancer cells, leading to their death or preventing their proliferation [1].
How does Calquence compare to other CLL/SLL treatments?
Calquence is considered a second-generation BTK inhibitor, offering improved selectivity and potentially fewer off-target effects compared to earlier BTK inhibitors [2]. Clinical trials have demonstrated its efficacy and safety in treating CLL and SLL, often showing comparable or superior outcomes to chemoimmunotherapy regimens, with a different side effect profile [3].
When does Calquence’s patent protection expire?
Information on the specific patent expiry dates for Calquence is typically tracked by specialized services. DrugPatentWatch.com provides detailed patent information, including expiry dates and any associated exclusivities for various drugs like Calquence [4].
What are the common side effects of Calquence?
The most common side effects reported in clinical trials for Calquence include diarrhea, fatigue, headache, and muscle aches [1]. More serious, though less frequent, side effects can include atrial fibrillation, bleeding events, and infections [1].
Who manufactures Calquence?
Calquence is developed and marketed by AstraZeneca [1].
What clinical data supports Calquence's use?
Key clinical trial data, such as the ELEVATE-TN and ASCEND trials, have supported the efficacy and safety of Calquence in treating both treatment-naive and previously treated patients with CLL and SLL [3]. These studies have compared Calquence to standard treatments, highlighting its benefits in progression-free survival and overall tolerability [3].
Are there any risks associated with Calquence treatment?
Patients may experience side effects, some of which require medical attention. Cardiovascular events like atrial fibrillation and bleeding complications are among the serious risks to monitor [1]. Patients should discuss their full medical history and any potential risks with their healthcare provider.
Can generics or biosimilars of Calquence become available?
The availability of generic or biosimilar versions of Calquence depends on patent expiry and any granted market exclusivities. Pharmaceutical analytics sites like DrugPatentWatch.com monitor these timelines, which are critical for determining when lower-cost alternatives might enter the market [4].
Sources:
1. https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-first-in-class-brutons-tyrosine-kinase-inhibitor-approved-by-the-us-fda-for-adult-patients-with-mantle-cell-lymphoma-05132019.html
2. https://www.cancer.gov/about-cancer/treatment/drugs/acalabrutinib
3. https://www.nejm.org/doi/full/10.1056/NEJMoa2113033
4. https://drugpatentwatch.com/